34 news items
DEADLINE ALERT for SOND, OCGN, VFS, and QDEL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
OCGN
SOND
3 Jun 24
) VinFast lacked sufficient capital to execute its purported growth strategy; (2) VinFast would be unable to meet its 2023 delivery targets; (3
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
OCGN
31 May 24
. The currently approved treatments for GA target only the complement pathway and require approximately 6-12 intravitreal injections annually. OCU410
DEADLINE ALERT for SOND, OCGN, VFS, and QDEL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
OCGN
SOND
29 May 24
targets; (3) accordingly, VinFast had overstated the strength of its business model and operational capabilities, as well as its post-Merger business
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
OCGN
28 May 24
-changing modifier gene therapies targeting blindness diseases—both rare and those affecting millions—in clinical trials," said Dr. Shankar Musunuri
DEADLINE ALERT for SOND, OCGN, VFS, and QDEL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
OCGN
SOND
22 May 24
) VinFast lacked sufficient capital to execute its purported growth strategy; (2) VinFast would be unable to meet its 2023 delivery targets; (3
qwcf2r57ctu2pc8o934esufm868gkkayldixm 4v6clgvpbsxgi
OCGN
20 May 24
the Company's 2026 BLA and MAA approval targets. OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication
76wzmdio3dyfsxzs99mjndmv484ti70wulcclqqcp126xql2
CKPT
HRT
OCGN
16 May 24
, 2024 Checkpoint is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition
0eee9lxh7b479y
OCGN
15 May 24
Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $5 price target.
so123e33n0v4ksj2cv 51y84mm060dv0r6obwn9oy3dfzbhpxhkc2afs
OCGN
15 May 24
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.5, along
vm6t0nh9nv yfnz
OCGN
15 May 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.
c45z9nao4vtgt5e3d4jeyxbgthbo9j0d25f9zgrubd5r0pb36uq0zh1re
CKPT
HRT
OCGN
12 May 24
is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel
yuwagblzja6e2jr7p zcc94h6xad9d6sro1vo
CKPT
HRT
OCGN
7 May 24
Checkpoint is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel
s4bfmruftw4o9fyx
OCGN
2 May 24
and on track to meet the Company's 2026 BLA and MAA approval targets. OCU400 is the first gene therapy program to enter Phase 3 with a broad retinitis
p772xqega6dlduz3bi9lvepcaomnnubrraq4qry
DD
DYAI
HCA
29 Apr 24
.
On April 5, 2023, Ladenburg Thalmann set a target price of $4, see
b1vsq2ptrtsra6o8ccna 38kepm8h
ADXN
ALT
ALTM
29 Apr 24
and maintained a $4 price target.
Cyclacel Pharmaceuticals, Inc
iqkku fwx214acsp9wxgwkraa33b3ql6nlcp9itmf
OCGN
29 Apr 24
trial is currently underway and on track to meet the Company's 2026 BLA and MAA approval targets. Between the U.S. and EU, nearly 300,000 people
mmw02idoemhyvjyhh z19zf6p
OCGN
26 Apr 24
filing targets. About AAV-hRORA (OCU410/OCU410ST) AAV
mb2p285iqfq qd7
AA
ACCD
BYND
22 Apr 24
and downgrades, please see our analyst ratings page.
Susquehanna raised the price target
0wnnduweex47l9ayivzfc9tv8dq5xs3rh59eq9f415ch
OCGN
19 Apr 24
therapies for GA targeting a single pathway of the disease, which has multifactorial and complex etiology," said Syed M. Shah, MD, Vice Chair of Research
27l0 qnluemt
CC
OCGN
15 Apr 24
to additional cash compensation if certain targets, including Free Cash Flow targets, were met. Similarly, pursuant to Chemours's Long-Term Incentive Plans